Gaucher disease therapy is administered in an I.V. infusion between three times a week and every four weeks initially and then at increased intervals for maintenance therapy. Cerezyme dosing was incorrectly reported in the April 10 issue of "The Pink Sheet" (p. 22) in its coverage of a hypothetical discussion of the drug as an illustration of orphan drug evergreening issues at BIO 2000
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth